Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Protara Therapeutics	Pluristem Therapeutics	Champions Oncology	X4 Pharmaceuticals	Ayala Pharmaceuticals
Symbol	NASDAQ:TARA	NASDAQ:PSTI	NASDAQ:CSBR	NASDAQ:XFOR	NASDAQ:AYLA
Price Information
Current Price	$15.83	$4.42	$11.33	$8.70	$10.29
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.4	1.8	1.8	1.4
Analysis Score	3.5	3.4	3.5	3.5	3.4
Community Score	2.6	2.9	2.2	2.8	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	0.0	1.7	1.7	0.0
Earnings & Valuation Score	0.6	0.6	1.9	1.3	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$47.67	$9.75	$16.00	$18.60	$24.20
% Upside from Price Target	201.12% upside	120.59% upside	41.22% upside	113.79% upside	135.18% upside
Trade Information
Market Cap	$190.78 million	$138.41 million	$154.39 million	$155.59 million	$135.52 million
Beta	1.17	2.53	1.2	0.53	N/A
Average Volume	97,363	714,374	31,967	111,413	35,754
Sales & Book Value
Annual Revenue	N/A	$20,000.00	$32.12 million	N/A	$2.33 million
Price / Sales	N/A	6,967.91	4.72	N/A	58.16
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	($21.67) per share	$2.20 per share	$0.45 per share	$10.37 per share	N/A
Price / Book	N/A	2.01	25.18	N/A	∞
Profitability
Net Income	$-14,990,000.00	$-29,150,000.00	$-1,980,000.00	$-52,810,000.00	$-17,790,000.00
EPS	N/A	N/A	($0.17)	($4.63)	N/A
Trailing P/E Ratio	0.00	0.00	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	75.53	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-4.18%	N/A	-850.81%
Return on Equity (ROE)	-45.45%	-86.51%	-29.93%	-47.06%	-625.24%
Return on Assets (ROA)	-41.09%	-68.23%	-7.41%	-35.89%	-70.31%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.24%	N/A
Current Ratio	42.99%	5.12%	1.18%	10.19%	8.63%
Quick Ratio	42.99%	5.12%	1.18%	10.19%	8.63%
Ownership Information
Institutional Ownership Percentage	83.11%	11.95%	52.84%	67.76%	12.81%
Insider Ownership Percentage	45.70%	4.90%	46.80%	4.90%	N/A
Miscellaneous
Employees	27	146	143	68	34
Shares Outstanding	11.23 million	31.53 million	13.39 million	17.38 million	13.17 million
Next Earnings Date	5/12/2021 (Estimated)	5/10/2021 (Estimated)	7/26/2021 (Estimated)	5/6/2021 (Estimated)	6/28/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Comparing Mesoblast (NASDAQ:MESO) and Ayala Pharmaceuticals (NASDAQ:AYLA) americanbankingnews.com - April 7 at 8:18 AM
	Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Receives Consensus Recommendation of "Buy" from Brokerages americanbankingnews.com - April 6 at 4:16 AM
	Ayala Pharmaceuticals (NASDAQ:AYLA) Posts Earnings Results, Misses Estimates By $0.15 EPS americanbankingnews.com - March 26 at 9:32 AM
	Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update finance.yahoo.com - March 25 at 9:10 AM
	Ayala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of Shares finance.yahoo.com - February 24 at 11:15 PM
	Ayala Pharmaceuticals raises $25M from private stock sale bizjournals.com - February 24 at 6:15 PM
	Ayala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16% finance.yahoo.com - February 22 at 1:13 PM
	Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors finance.yahoo.com - February 19 at 2:34 PM
	Companies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In Growth finance.yahoo.com - February 19 at 9:33 AM
	ACIU & Alzheimer's Vaccine, GNMK Rallies, ESSA's Prostate Cancer Drug On Track, MNPR On Watch nasdaq.com - February 12 at 7:35 AM
	NVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial nasdaq.com - January 29 at 2:14 AM
	Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 ... apnews.com - January 28 at 11:10 AM
	Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer finance.yahoo.com - January 28 at 11:10 AM
	Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap ... apnews.com - January 13 at 8:55 PM
	Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference finance.yahoo.com - January 13 at 8:55 PM
	Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference finance.yahoo.com - January 5 at 11:57 AM
	Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in ... omaha.com - January 4 at 10:54 PM
	Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study finance.yahoo.com - January 4 at 12:53 PM
	Ayala Pharmaceuticals Inc reuters.com - December 16 at 7:44 AM
	Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy? feedproxy.google.com - November 26 at 9:12 PM
	Growth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64% nasdaq.com - November 20 at 10:08 AM
	Ayala Pharmaceuticals EPS misses by $0.03, beats on revenue seekingalpha.com - November 19 at 8:40 AM
	Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update finance.yahoo.com - November 17 at 9:49 AM
	Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences finance.yahoo.com - November 5 at 9:48 AM
	Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for ... bakersfield.com - September 18 at 1:46 PM

Date	Company	Brokerage	Action
3/21/2021	Protara Therapeutics	Oppenheimer	Reiterated Rating
10/19/2020	Protara Therapeutics	Cowen	Initiated Coverage
7/29/2020	Protara Therapeutics	Guggenheim	Initiated Coverage
1/22/2020	Protara Therapeutics	LADENBURG THALM/SH SH	Initiated Coverage
12/10/2020	Pluristem Therapeutics	Jefferies Financial Group	Downgrade
12/7/2020	Pluristem Therapeutics	HC Wainwright	Reiterated Rating
10/9/2020	Pluristem Therapeutics	Dawson James	Reiterated Rating
5/15/2020	Pluristem Therapeutics	Maxim Group	Reiterated Rating
3/22/2021	Champions Oncology	Roth Capital	Boost Price Target
11/27/2019	Champions Oncology	Benchmark	Initiated Coverage
7/24/2019	Champions Oncology	Janney Montgomery Scott	Downgrade
2/27/2019	Champions Oncology	National Securities	Initiated Coverage
7/17/2018	Champions Oncology	Craig Hallum	Initiated Coverage
12/17/2020	X4 Pharmaceuticals	Brookline Capital Management	Initiated Coverage
11/30/2020	X4 Pharmaceuticals	B. Riley	Reiterated Rating
11/9/2020	X4 Pharmaceuticals	Canaccord Genuity	Lower Price Target
3/26/2020	X4 Pharmaceuticals	Citigroup	Lower Price Target
6/7/2019	X4 Pharmaceuticals	Stifel Nicolaus	Initiated Coverage
1/25/2021	Ayala Pharmaceuticals	Noble Financial	Reiterated Rating
8/13/2020	Ayala Pharmaceuticals	Raymond James	Reiterated Rating

(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources